UBRS21032 / HCRN-BRE17-141 / O'Regan
Basic Study Information
Purpose:
Patient will be treated with neratinib, an aromatase inhibitor and trastuzumab for
24 weeks prior to surgery, following an initial 3 weeks of neratinib alone, aromatase
inhibitor alone or the combination of neratinib and an aromatase inhibitor. A breast
biopsy will be performed prior to Day 1 of week 4 of treatment. Following surgery,
patients will receive standard of care HER2-directed and endocrine therapy at the
treating physician's discretion.
Location: University of Rochester Medical Center
Lead Researcher (Principal Investigator)
Lead Researcher:
Ruth O'Regan
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search